Medical artificial intelligence has to earn its place in a system where mistakes carry consequences and budgets already face pressure. A useful model may help clinicians interpret a scan, organize a patient record or identify a promising drug candidate. The investment question is whether that capability produces a measurable benefit that customers will pay for repeatedly. Technical progress alone...
About the Author Habib Ur Rehman
Habib is an equities analyst who writes and edits stock research focused mostly on the AI economy. He's also responsible for content strategy at Insider Monkey. Prior to working here, he built his foundation in… Habib is an equities analyst who writes and edits stock research focused mostly on the AI economy. He's also responsible for content strategy at Insider Monkey. Prior to working here, he built his foundation in financial journalism while working on digital business coverage at the web desk of Dunya News, one of Pakistan’s largest media organizations. He holds a master’s in data science. In his free time, Habib enjoys competitive shooting, Sci-Fi novels and philosophy of AI. Read more Read less Disclosure Author disclosure:
No author disclosure was provided for this article.
This article is provided for informational purposes only and does not constitute financial, investment, legal, or tax advice.
Read our Disclosure Policy.
NYSE:EVH Headline NYSE:BSX NYSE:ORCL NASDAQ:QSI NASDAQ:OMCL NASDAQ:ABSI NASDAQ:CSTL NASDAQ:IRTC NASDAQ:LUNG NASDAQ:RXRX Daily Newsletter Omnicell Inc (NASDAQ:OMCL) Oracle Corporation (NYSE:ORCL) Evolent Health Inc. (NYSE:EVH) Absci Corporation (NASDAQ:ABSI) Pulmonx Corporation (NASDAQ:LUNG) iRhythm Holdings Inc. (NASDAQ:IRTC) Quantum-Si incorporated (NASDAQ:QSI) Castle Biosciences Inc. (NASDAQ:CSTL) Boston Scientific Corporation (NYSE:BSX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) Show more... Show less
